The human oral cavity harbors a substantial and continuously evolving load of microbial species. Many infectious diseases, including periodontal diseases, appear to be infections mediated by the overgrowth of commensal organisms, rather than by the acquisition of an exogenous pathogen. As microorganisms evolve more rapidly than their hosts, immune mechanisms that determine the ecological balance of commensal organisms also need to change to preserve homeostasis.
severity and progression of periodontal disease and both the innate and the adaptive immune responses may be involved. The knowledge of how immune mechanisms and inflammatory responses are regulated is important for understanding the pathogenesis of complex diseases, such as periodontitis; in addition, it is important to continue considering mechanisms that regulate inflammatory responses because they may open up novel therapeutic targets.
Epoxyeicosatrienoic acids (EETs) are biologically active metabolites of arachidonic acid that are generated by the activity of cytochrome p450 (CYP) enzymes. Once formed, EETs are unstable, being rapidly converted into less active or inactive dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (sEH). 2 This conversion may be prevented by inhibitors of sEH (sEHI), so EETs can be stabilized, prolonging their biological effects. 3 Studies on these effects emphasize the role of EETs in vasodilatation of systemic vessels and control of blood pressure, grounding their promise in the treatment of vascular diseases, such as atherosclerosis and hypertension. 2, 3 Emerging additional benefits have been described for EETs, which are currently recognized as potent anti-inflammatory agents. 2, 4 They can inhibit cytokine-induced inflammation signaling mediated by nuclear factor-kappaB, thus reducing the expression of proinflammatory mediators and cell adhesion molecules. 5 Systemic overexpression of human CYP2J2, a CYP epoxygenase isoform that produces EETs, led to a significant reduction in the tumor necrosis factor-alpha (TNF-α)-induced high plasma levels of adhesion molecules and inflammatory cytokines in rats, suggesting that EETs and other epoxy fatty acids act as anti-inflammatory mediators. 6 In addition, sEH pharmacological inhibitors, such as 1-trifluoromethoxyphenyl-3-(1-propionylpiper idin-4-yl) urea (TPPU), have been the focus of in-depth investigation because, by reducing the metabolism of EETs, these inhibitors were demonstrated to alleviate inflammatory and fibrotic diseases in animal models. [7] [8] [9] [10] Therefore, sEH may be an important target for the modulation of periodontal disease and bone resorption.
In this study, using an animal model of periodontitis, we explored the molecular mechanisms by which TPPU may modulate the immunological response to avoid disease-related bone loss.
| MATERIAL AND ME THODS

| Animals
Male mice were maintained in standard conditions, under a 12-hour light-dark cycle with food and water ad libitum. Six mice per group, weighing 20-25 g, were age-matched. All procedures were carried out in agreement with the standards for the care of laboratory animals, as outlined in the NIH Guide for the Care and Use of Laboratory Animals, and were approved by the Animal Resource Services of the University (University of California).
| Periodontitis model and treatments
Aggregatibacter actinomycetemcomitans (JP2) was cultured under anaerobic conditions to ensure viability and virulence. The mice received 1 × 10 9 colony-forming units/mL of A. actinomycetemcomi tans, diluted in 100 μL of phosphate-buffered saline containing 2% carboxymethylcellulose, orally. Oral colonization of A. actinomyce temcomitans was performed before, at day 0, and at the end of the experiment, as previously described. 11 The solution was placed in the oral cavity, and the procedure was repeated 2 and 4 days after the first inoculation. Treatment with TPPU, which was dissolved in PEG400, was initiated after the last inoculation of bacteria by oral gavage. The dose of TPPU used was 1 mg/kg/d for 15 days, as previously tested. 10 The negative control group consisted of uninfected mice (sham-infected), and mice in the positive control group were infected with A. actinomycetemcomitans and received vehicle only (PEG400). The mice were continuously weighed every 2 or 3 days after TPPU treatment begin. The day after the treatment period ended, the mice were killed by cardiac puncture after anesthesia with xylazine/ketamine. The whole buccal and palatal periodontal tissues of the upper and lower molars were collected, weighed, and the portions of gingival tissue were separated into two halves: one half was used for extraction of protein and the other half was used for extraction of mRNA. The amount of gingival tissue for protein extraction was triturated and homogenized in 300 μL of the appropriate buffer containing protease inhibitors (Sigma-Aldrich, St Louis, MO, USA), followed by centrifugation for 10 minutes at 10 000 g.
The supernatant was rapidly frozen and stored at −70°C for further gene expression analyses or western blotting.
| Quantification of alveolar bone loss
Evaluation of alveolar bone loss was performed as described previously. 11 The jaws were removed and defleshed, then immersed overnight in 3% hydrogen peroxide, washed in phosphate-buffered saline, and stained with 1% methylene blue. Horizontal bone loss was assessed morphometrically by measuring the distance between the cement-enamel junction and the alveolar bone crest of the first and second molars. Measurements were made at 14 buccal sites per mouse, under a microscope, and bone measurements were analyzed using the Image J software (Bethesda, MD, USA). Random and blinded measurements were made by the same calibrated person, achieving intra-examiner reproducibility of >90%.
| Western blotting
Tissues were lysed and clarified by centrifugation, and protein concentrations were determined using the bicinchoninic acid pro- 
| PCR Array
The RNeasy Micro Kit (Qiagen) was used for total RNA extraction, and 300 ng was retrotranscribed using the RT 2 First Strand Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. 
| Statistical analysis
Results were expressed as mean ± SD. Data were analyzed using the Shapiro-Wilk test and were found to be normally distributed. Oneway ANOVA followed by Tukey's test was applied for post hoc analysis. Significance was considered at a level of 0.05.
| RE SULTS
The effect of oral administration of TPPU on A. actinomycetem comitans-induced periodontal bone resorption was assessed by quantifying, in all mice, the distance between the cement-enamel junction and the alveolar bone crest during the experimental pe- 
| D ISCUSS I ON
Participation of the immune system in response to the aggressive growth and tissue damage stimulated by microorganisms is important because many of the immunological factors involved in response to the bacteria can induce a change in homeostasis and affect the alveolar bone. 13 Studies have shown that EETs play a key role in the antiinflammatory process and would have a beneficial effect in preventing bone loss caused by periodontal disease. 10, 14, 15 EETs are rapidly metabolized by sEH and thus EETs have a short half-life, making natural EETs difficult to use pharmacologically. Therefore, TPPU was developed to increase the half-life of EETs and thus enhance their biological effects. 16 As demonstrated, the A. actinomycetemcomitansinduced periodontal disease resulted in an increase in the expression of sEH which was abrogated when the mice were treated with TPPU. This is the first report demonstrating expression of sEH in structures on the surface of a variety of microorganisms. 18 In accordance with our findings in gingival tissue, the levels of MBL in plasma have been reported to increase during infections and inflammatory processes. 19 The concentrations of MBL in plasma were not significantly different in moderate and severe periodontitis compared with controls, and MBL deficiency was not related to susceptibility for periodontitis. 20 In our disease model, the immune response was provoked by inoculating A. actinomycetemcomitans; this may explain the dramatically increased expression of MBL.
Significant attention has been given to pattern recognition receptors similar to the toll receptors. 21 TLRs 1 and 9 were significantly downregulated in the TPPU-treated mice. TLRs in periodontal disease play a key role in triggering the inflammatory response because they can mediate the release of inflammatory cytokines. 17 Recently, TLR-2 was shown to form heterodimers with TLR-1 and TLR-6 that recognize triacylated lipopeptides from gram-negative bacteria. 22 Interestingly, TLR-2/1 ligand induces osteoclastic bone resorption in mouse culture cells. 23 Human type I IFNs are produced and released by host cells in response to the presence of several pathogens. In inflammation, IFNs possess both pro-and anti-inflammatory functions, depending on the context of the particular pathology. 24 Recently, an inhibitory role for type I IFNs in blocking IL-1β production has been reported. 25 In this study, the IFN-β1 proteins are up-regulated, suggesting the importance of TPPU in controlling the inflammatory process in gingival tissue.
T helper 1 (Th1) cells secrete IL-2 and IFN-γ 26 and there is strong evidence that the release of IFN-γ results in increased loss of alveolar bone during periodontal infections. 27 Besides, high levels of IFN-γ in patients with periodontitis are related to the severity of the disease. 28 Thus, the decreased expression of IFN-γ by treatment with TPPU may explain the decrease of bone resorption. In addition, TPPU also reduced the expression of receptors CD4 and CD8, and consequently lymphocytes.
The chemokine receptor, CCR, is expressed in pathological situations and is responsible for the development and function of the immune system during the inflammatory process. 29, 30 The administration of TPPU decreases the expression of CCR6, CCR4, and CCR8.
Studies show that CCR6 is a specific marker for Th17 cells and regulatory T cells (Tregs) . 31 Furthermore, we demonstrated that treatment with TPPU also modulated the CXCR3 receptor. This receptor is responsible for guiding cells (mainly CD8 + T cells) out of the lymphoid compartment toward the sites of inflammation.
32
CCR4 and CCR8 are expressed predominantly in Th2 cells and Tregs. These two chemokines provide guidance to the T cells that express CCR4 so that they can reach the inflamed mucosa. In our study it was demonstrated that a classical standard Th2 cytokine, IL-5, was also decreased in the group of animals treated with TPPU. This cytokine, along with IL-6 and TNF-α, can promote survival of plasma cells in the presence of inflammation. 47 The effects of IL-5 include the maintenance of survival and functions of B cells and eosinophils, and a lack of functional genes or receptors to IL-5 induce deficiencies in the development of these cells. 48 Interleukin-13, which is up-regulated in TPPU-treated mice, is another potent modulator of human monocyte/macrophage and B-cell function. Monocyte/macrophage major histocompatibility complex class II and several integrin molecules are up-regulated by IL-13; 49 however, the production of IL-1α, IL-1β, IL-6, IL-8, and TNF-α are inhibited by IL-13, suggesting an anti-inflammatory role. 49 The plasma protein serum amyloid P-component (SAP) reduces neutrophil adhesion, inhibits the differentiation of monocytes into fibroblast-like cells, and promotes phagocytosis of cell debris by macrophages. Together, these effects of SAP reduce important aspects of inflammation and fibrosis 50 which help to explain the decreased bone resorption. sEH inhibitors have been shown, in multiple studies, to reduce inflammation and fibrosis. 2, 4, 7, 9, 10 In addition, it was observed that decrease of STAT4, a transcription factor for IL-12, IL-23, and IFN-1, leads to differentiation of Th1 and Th17 cells, as well as to the activation of monocytes, and stimulates the production of IFN-γ. By leading to the production of IFN-γ and IL-17, this transcription factor directs T cells to differentiate into Th1 cell lines. STAT4 in other cellular subtypes can also contribute to the progression of diseases as a result of the increase in inflammatory cytokines, prevention of apoptosis, presentation of antigens, or antibody production. 51 The immunomodulation of this STAT is an important clue of the effect of TPPU.
Another aspect considered in our study was the decreased expression of the Lyz2 and Mx1 genes in the mice treated with TPPU. 
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